Peroxisome proliferator-activate d receptors (PPARs) are members of the nuclear receptor subfamily of transcription factors with pleiotropic effects on intra-and extracellular lipid metabolism, glucose homeostasis, cell proliferation, control of in ammation, and atherosclerosis. Three PPARs, namely a , d , and c have been identi ed with distinct tissue distribution patterns and metabolic functions. PPAR-a is predominantl y expressed in brown adipose tissue, liver, kidney, duodenum , heart, skeletal muscle, and vascular endothelial cells and is involved in the control of lipoprotein metabolism, fatty acid oxidation, and the cellular uptake of fatty acids. PPAR-c is highly expressed in brown and white adipose tissues and, to lesser extent, in large intestine, retina, and some parts of the immune system, and plays a critical role in adipocyte differentiation and fat deposition. PPAR-d shows a widespread tissue distribution but its regulation and functions are not yet known. Considerabl e evidence indicates that PPARs (PPAR-a and PPAR-c ) have bene cial effects in in ammatory diseases, including atherosclerosis, through regulation of cytokine production, adhesion molecule expression on the endothelial cells, brinolysis, and modulation of monocyte-derive d macrophages . In this review, the general and speci c roles of the PPAR isotypes and their implications in the control of vascular in ammation and atherosclerosis are discussed.
INTRODUCTION
Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear receptor subfamily of transcription factors that encode receptors for steroid and thyroid hormones, vitamin D, and retinoic acid. To date, three different isotypes have been described in various species: PPAR-a , PPAR-d (also called PPAR-b ), and PPAR-c . PPAR-a , the rst PPAR identi ed, is mostly expressed in brown adipose tissue, liver, kidney, intestine, pancreas, heart, skeletal muscle, lung, placenta, and vascular endothelial cells (2, 10, 31, 51) . Experimental studies have shown that PPAR-a is involved in the control of lipoprotein metabolism (73, 74) , fatty acid oxidation, in particular beta-oxidation (20, 50) , and the cellular uptake of fatty acids (55) . In mice lacking PPAR-a , inhibition of cellular fatty acid ux caused massive hepatic and cardiac lipid accumulation, hypoglycemia and death, suggesting a pivotal role for PPAR-a in lipid and glucose homeostasis in vivo (20) . Some natural and synthetic PPAR-a ligands have been identi ed, and are listed in Table 1 . PPAR-c , probably the best-characterized receptor, plays a critical role in adipocyte differentiation and fat deposition, and it is expressed predominantly in brown and white adipose tissues and, to lesser extent, in large intestine, retina, and some parts of the immune system (10, 51) .
Activation of PPAR-c by agonists like the thiazolidinedione (TZD) class of compounds promotes adipogenesis and terminal differentiation of preadipocyte broblasts into mature adipocytes, which suggests that these drugs can modulate cellular differentiation. Various TZDs have been used as insulin sensitizers for the treatment of Type II diabetes. These drugs produce their antihyperglycemic effect in Type II diabetic patients by selectively enhancing or partially mimicking certain actions of insulin and thereby increasing insulin-dependent glucose disposal and reducing hepatic glucose output (44) . Studies in the PPAR-c gene knockout mouse model have shown that homozygous PPAR-c null mice die in development, whereas heterozygous mice carrying a single copy of the PPAR-c gene (PPAR-c / ) display greater insulin sensitivity (52) . Other new TZDs and non-TZD compounds are listed in Table 1 . Chronic TZD treatment in rodents or primates has been shown to cause a striking morphologic change in the brown adipose tissue, consisting of replacement of the normal adipocyte phenotype (centrally placed nucleus with numerous small cytoplasmic lipid vacuoles) by adipocytes of increased size with fewer, large lipid droplets in the cytoplasm (34) . In more advanced cases, the adipocyte nucleus is displaced to the periphery of the cell by a single large lipid vacuole with a morphologic shift toward a white adipocyte phenotype (Figures 1 and 2 ). This morphologic alteration has been variously described as white adipocyte conversion, differentiation, or steatopathy. White adipocyte differentiation or conversion may not be appropriate in the very early stage or mild change in which the cytoplasm has multiple but large lipid vacuoles with no apparent nuclear displacement. For this reason, we prefer the term "cytoplasmic macrovesiculation" of brown adipocytes.
PPAR-d is ubiquitously expressed in a number of different tissues in rat and human and is found in higher amounts than PPAR-a and PPAR-c . Both natural and synthetic ligands have been identi ed, and include polyunsaturated fatty acids and the synthetic prostacyclin (PGI) analog carbaprostacyclin and L-165041 (22, 39) . Recently, Lim et al (42) , using L-165041, have shown that PPAR-d is involved in the regulation of embryo implantation and that cyclooxygenase -2-de cient mice exhibit multiple reproductive problems including defects in blastocyst implantation and decidualization. These defects can be rescued by the administration of FPO FIGURE 1.-Typical interscapular brown adipose tissue in a control rat. Note adipocytes with centrally placed nuclei and numerous small cytoplasmic lipid vacuoles. H&E. 400. PGI 2 and L-165041, suggesting that PPAR-d plays an important role in the reproductive function (41, 42) . Preliminary results also suggest that PPAR-d is involved in regulation of lipid metabolism (39) and carcinogenesis (30) . However, many critical functions remain to be elucidated by future investigations (2, 10) . For this reason, our discussion will focus mainly on PPAR-a and PPAR-c subtypes.
Several studies have recently shown that PPARs have a role expanding beyond modulation of lipid metabolism (as in potential therapies for diabetes and obesity) with functions in cell cycle control, carcinogenesis, in ammation, and atherosclerosis. Experimental studies indicate that PPARs may have a preventive role in the pathogenesis of atherosclerosis by regulating cytokine production, adhesion molecule expression on endothelial cells, brinolysis, modulation of monocyte-derived macrophages, and proliferation of vascular smooth muscle cell (VSMC) (37, 44) . On the other hand, in vitro data from Tontonoz et al (79) and Nagy et al (58) suggest that PPAR-c is upregulated in activated macrophages and might increase foam cell differentiation and activity in internalizing comprehensive study con rming the existence of PPAR-c in the artery wall of humans and rats (37) . PPARs (PPRAR-a and PPAR-c ) are clearly expressed in atherosclerotic lesions, predominantly in the macrophages but also in the endothelial cell layer and the VSMCs. However, expression of PPAR-c in VSMCs is somewhat controversial. In human aortic VSMCs, Stael et al (75) found very low levels of PPAR-c mRNA relative to PPAR-a . In contrast, Law et al (37) have found signi cant PPAR-c expression in VSMCs, as well as evidence for PPAR-c regulated target genes. Considerable evidence suggests that neither expression nor overexpression of PPARs causes the pathologic changes associated with atherosclerosis. On the contrary, induction of PPARs has been shown to have bene cial (inhibitory) effects on atherosclerosis through regulation of cytokine production, adhesion molecule expression on endothelial cells and brinolysis, and modulation of monocyte-derived macrophages and apoptosis (5, 44) .
The process of atherosclerosis is a veritable multistep process and involves multiple cell types: accumulation of lipids and extracellular matrix in the vessel (arterial) wall; in ltration of macrophages; adhesion of circulating monocytes to the endothelium with subsequent transmigration; maturation of monocytes to macrophages with acquisition of scavenger receptors that allow them to recognize and take up oxidatively modi ed lipoproteins; and stimulation of macrophages, T-lymphocytes, smooth muscle and endothelial cells to secrete cytokines, growth factors, and other mediators that elicit a local in ammatory response (14) . Figure 3 depicts some of the known modulating roles of PPAR agonists in atherogenesis and in ammation.
Effects of PPARs in the Recruitment of In ammatory Cells
One of the rst steps in atherogenesis is chemotactic attraction with subsequent entry of in ammatory cells into the vessel wall. One family of proteins that has received recent attention as a signal for attracting in ammatory cells are chemokines or in ammatory cytokines. Chemokines are complex proteins secreted by multiple cell lines including endothelial cells, which interact with cognate receptors on the surface of various cells. Two classes of chemokines that have been implicated in atherosclerosis are CXC-chemokines and the CC-Chemokine, monocyte chemotactic protein-1 (MCP-1) (46, 56, 62) . The CXC chemokines include gamma interferon (IFN-gamma)-inducible protein 10 (IP-10), monokine induced by IFN-gamma (Mig), and inducible T-cell alpha-chemoattractant (I-TAC). CXCchemokines play an important role in the regulation of monocyte-endothelial interactions in atherosclerosis (8) . Marx et al (46) have shown that PPAR-c agonists inhibit expression of IP-10, Mig, and I-TAC from human endothelial cells. Similar effects were not observed with PPAR-a agonists. Monocyte chemoattractant protein-1, produced by vascular endothelial cells, modulates monocyte and T cell recruitment and activation, including regulation of expression of complement proteins, interleukin-1 (IL-1), and tissue factor (69) . The PPAR-c agonist has been shown to inhibit the production of MCP -1 in cytokine [IL-1b or tumor necrosis factor-a (TNF-a )] treated human vascular endothelial cells (56) . The importance of MCP-1 in atherogenesis has recently been shown using both apo E knockout and LDL-R knockout mouse models of human atherosclerosis. In both models, atherosclerotic lesions were reduced markedly when MCP-1 expression was also knocked out (9, 27, 66) .
Expression of adhesion molecules on the endothelial cell surface is also critical for recruitment of leukocytes to the site of atherosclerotic lesions. Signal-transduction pathways for these binding molecules include the translocation of the transcription factor nuclear factor-kB (NF-j B). Intracellularly generated oxygen-derived free radicals (ODFR) also play a major role in this process. More recently, PPAR-c activators have been found to inhibit the expression of vascular cell adhesion molecule-1 (VCAM-1) and intercellular cell adhesion molecule-1 (ICAM-1) in activated human endothelial cells (63) . In human umbilical vein endothelial cells, troglitazone has been shown to reduce expression of VCAM-1, ICAM-1, and E-selectin induced by TNF-a alone or in combination with different amounts of oxidized-LDL; this reduction was paralleled by a signi cant fall in NF-j B translocation, suggesting that troglitazone may have prevented NF-j B-mediated adhesion molecule expression by exerting its antioxidant effect on ODFR (17) . Similarly, PP signaling and TNF-a induced expression of VCAM-1, and subsequent adherence of monocytes on human endothelial cells (48) .
Effects of PPARs in Macrophage Activation and Function
Activated macrophages play a critical role in atherogenesis by secreting substances that contribute to atherosclerotic plaque formation. It has been shown that PPAR-c agonists suppress monocytic elaboration of pro-in ammatory cytokines (32) . Expression of PPAR-c is increased markedly in activated macrophages, and stimulation of PPAR-c by either locally produced prostaglandin metabolites or syn-thetic ligands inhibits expression of scavenger receptor A and gelatinase B [matrix metalloproteinase-9 (MMP-9)] (67).
Plutzky (64) reported that the expression of PPAR-c in monocytes/macrophages in human atheroma, with activation of PPAR-c in human monocyte-derived macrophages by PPARc agonists, troglitazone and 15-deoxy-delta-prostaglandi n J2 (15d-PGJ2), inhibited MMP-9 expression and functional gelatinolytic activity in a dose-dependent manner. Because MMP-9 is responsible for degradation of collagen and other matrix components of vessel walls such as elastin, its inhibition would be expected to be protective.
Effects of PPARs in Vascular Smooth Muscle Cells
Migration and proliferation of vascular smooth muscle cells (VSMC) are critical events in the progression of atherosclerosis. PPAR-c is expressed in both human VSMC and endothelial cells, and PPAR-c activation in VSMC has been shown to inhibit MMP-9 expression and functional activity (45, 47) . The PPAR-c agonist has also been shown to inhibit b-broblast growth factor (b-FGF)-induced VSMC growth and platelet-derived growth factor (PDGF)induced VSMC migration as well as intimal hyperplasia after endothelial injury in rats (38) . Another vasoactive peptide, endothelin-1 (ET-1), is produced mainly by vascular endothelial cells and is involved in regulation of vascular tone and smooth muscle cell proliferation. PPAR-c agonist treatment inhibits thrombin-induced ET-1 biosynthesis, indicating a novel role in vascular endothelial function (18) . In human aorta and coronary artery myocytes in vitro, troglitazone attenuates mitogen-induced DNA synthesis, inhibits cell migration, and prevents c-fos expression (3). Troglitazone also inhibits intimal hyperplasia in normal and insulin-resistant rats in vivo, and more recently, has been found to upregulate cytokine-stimulated nitric oxide (NO) synthesis in the VSMC. This activity may have important implications for inhibition of atherosclerosis, because NO plays a preventive role in atherogenesis (29) . Goetze et al (25) reported that troglitazone inhibits both angiotensin II-induced nuclear translocation of extracellular signal-regulated kinase 1/2 and the nuclear activity of its upstream signaling kinase, protein kinase Cf in rat aortic smooth muscle cells. Because extracellular signal-regulated kinase 1/2 nuclear translocation may be a critical signaling step for multiple growth factors that stimulate VSMC proliferation and migration, troglitazone may provide a new therapeutic for the prevention and treatment of atherosclerosis (25) .
Effects of PPARs in Apoptosis and Other Functions
PPAR-a and PPAR-c agonists have been shown to induce apoptosis of differentiated human monocyte derived macrophages that participate in the control of in ammation and atherosclerotic plaque formation (5, 14) . PPAR-c activation resulted in a pronounced induction of apoptosis, whereas PPAR-a activators are much less pro-apoptotic in unstimulated differentiated macrophages. Apoptosis induction by PPAR-c ligands was more pronounced in macrophages activated with TNF-a and IFN-c (14) . Furthermore, PPAR-c agonists inhibited the transcriptional activity of the NF-j B P65/RelA subunits, suggesting that PPAR-c agonists induce macrophage apoptosis by interfering negatively with the antiapoptotic NF-j B signaling pathway (14) . NF-j B is a member of the Rel family of proteins that can either homo-or heterodimers and regulates gene expression. It has been suggested that NF-j B activation may have an important role in atherosclerosis, because oxidized LDL and an atherogenic diet activate the NF-j B complex. Increased NF-j B activity has been demonstrated in smooth muscle cells, endothelial cells, and macrophages in human atherosclerotic plaques (11) . Decreased NF-j B activity reduces COX2 activity, thus the reducing in ammatory process through inhibition of cytokine and prostaglandin production (74) . At present, effects of PPAR-a agonist on NF-j B activity are uncertain and may have different effects in separate species. PPAR-a agonist has been shown to decrease NF-j B activity in humans but not rodent VSMCs (40, 61, 68) . In addition, PPAR-c agonists may have a therapeutic potential for improving endothelial dysfunction by downregulating gene expression of plasminogen activator inhibitor type-1 (PAI-1), a major physiologic inhibitor of brinolysis and a predictor for risk of myocardial infarction and venous thrombosis (33) .
Anti-atherosclerotic Effects of PPARs in In vivo Studies
Although in vivo con rmation of the anti-atherogenic role of PPARs is still incomplete, the evidence implicating PPARs as important modulators of atherogenesis is mounting. Studies on the effect of TZD in patients with Type II diabetes demonstrated that a short period of treatment with troglitazone produced a signi cant reduction in carotid wall thickness (measured by B-mode ultrasound), a marker of early stages of atherosclerosis (53) . A recent study assessed intimal hyperplasia by intravascular ultrasound following stent implantation. After 6 months, patients treated with diet alone experienced a 49% occlusion of the lumen within the stent.
However, patients treated with troglitazone experienced a smaller (28%) occlusion of the lumen (77) . Similarly,brates that activate PPAR-a seem to slow down progression of atherosclerosis both in humans and rodents (12, 21, 24) . Law et al (38) examined the response of the rat aorta to balloon catheter injury. Inhibition of vascular smooth muscle growth and intimal hyperplasia, as assessed by measuring neo-intimal medial thickness, occurred after 14 days of treatment with troglitazone. The effects of troglitazone on a model of atherosclerosis, the LDL-receptor-de cient mouse, have been studied (15) . In these mice, troglitazone inhibited the extent of vascular lesions (measured by en face imaging of Sudan IV stained aortae) by 29% in high-fat diet animals and 42% in high-fructose diet animals with concomitant decrease in macrophage content. Similarly, troglitazone has been shown to decrease medial area (mm 2 ) of aortic wall, measured by histomorphometry in the noninsulin-dependent diabetes mellitus of Otsuka Long Evans Tokushima fatty rats (54) . These ndings support the notion that PPAR-c agonists are anti-atherogenic.
PPARS AND INFLAMMATION
Both PPAR-a and PPAR-c participate in modulation of the in ammatory process. The rst indication that PPAR-a could be implicated in control of the in ammatory response was recognition that PPAR-a is a ligand for Leukotriene B4, a potent chemotactic agent that initiates, coordinates, sustains, and completes the in ammatory response (19) . A role for PPAR-a as an anti-in ammatory factor was supported by studies in mice that are de cient in PPAR-a . These mice exhibit a prolonged response to in ammatory stimulus (19) . Inhibition of the cyclooxygenase step of arachidonic acid metabolism by PPAR-a is another mechanism by which PPAR-a agonists appear to inhibit in ammation in endothelial cells (19) . COX1 is constitutively expressed in most cell types, yet COX2 is rapidly induced by growth factors and cytokines in in ammation. PPAR-a activation negatively regulates COX2 activity without affecting COX1. In addition, PPAR-a appears to downregulate the activity of NF-j B with reduced production of interleukins (ILs). PPAR-a ligands have been shown to inhibit IL-1 induced production of IL-6 and prostaglandin in human aortic smooth muscle cells (74) .
Like PPAR-a , PPAR-c seems to have anti-in ammatory properties. Activation of PPAR-c has been shown to antagonize the activity of activation protein-1 (AP-1), Stat 1, and NF-j B, which are known for their positive control on cytokine gene expression (67) . In phorbol ester-treated human monocytes, PPAR-c reduces secretion of TNF-a , IL-6, and IL-1B. PPAR-c is also upregulated in activated macrophages and inhibits the secretion of inducible NO synthase; of gelatinase B, which is involved in tissue damage; and of scavenger receptors, which have a role in cell adhesion events and uptake of oxidized LDL. Nonsteroidal anti-in ammatory drugs can reduce cytokine production by monocytes at doses higher than those required for inhibition of COX, thus explaining why these drugs work better when given at high dosage in chronic in ammatory diseases, such as, rheumatoid arthritis. PPAR-c agonists appear to ameliorate rheumatoid arthritis through the suppression of macrophage activation (67). More recently, drugs of the TZD class, and the natural ligand 15d-PGJ2 have been shown to inhibit the b -amyloid-stimulated secretion of pro-in ammatory products such as IL-6 and TNF-a by neuronal microglia and monocytes that are responsible for neurotoxicity and astrocyte activation. Furthermore, PPAR-c agonists arrested the differentiation of monocytes into activated macrophages and inhibited the expression of COX2 (16) . Su et al (76) have shown that TZD markedly reduces colonic in ammation in a mouse model of in ammatory bowel disease (IBD). These anti-in ammatory effects suggest that PPAR-c agonists may provide a novel therapeutic approach to both Alzheimer's disease and IBD (16, 76) .
PRO-ATHEROSCLEROTIC AND PRO-INFLAMMATORY
EFFECTS OF PPAR-c AGONISTS The possibility that PPAR-c agonists might have proatherogenic effects has been raised from the nding that PPAR-c is activated by oxidized lipid components derived from LDL and colony stimulating factors in human atheroma monocyte/macrophages. PPAR-c is also expressed at high levels in the foam cells of atherosclerotic lesions. Enhanced PPAR-c expression also induces transcription of a scavenger receptor in monocyte/macrophages so that these cells acquire the ability to bind and internalize oxidized LDL, a potentially pro-atherosclerotic effect (79) . Also, Chen et al (13) have shown that PPAR-c is expressed in human vascular endothelial cells and that it can be activated by oxidized-LDL and troglitazone; PPAR-c activation is associated with increased expression of ICAM-1 and enhancement of monocyte binding to endothelial cells, suggesting that PPAR-c signaling pathway might contribute to the atherogenicity of oxidized-LDL in vascular endothelial cells. This increased ICAM-1 expression, however, contradicts the results of other researchers in which troglitazone has been shown to have an inhibitory effect on ICAM-1 expression in human endothelial cells (17, 63) . Furthermore, PPAR-c activators have been shown to inhibit human endothelial cell angiogenesis by inducing apoptosis via caspase-3 mediated process (6) . Inappropriate apoptosis in a large vessel may cause structural weakness in an existing atherosclerotic plaque and may promote subsequent plaque rupture, which may predispose to embolism or stroke (60) .
Shu et al (71) have shown that PPAR-c activation failed to block the production of TNF-a and IL-6 in monocytes or macrophages in cell-based in vitro assays. The failure to block the cytokine production was further shown in an in vivo study with lean and db/db mice treated with a potent TZD, and subsequently challenged with lipopolysaccharide (LPS). It was found that the administration of TZD resulted in a slight increase in TNF-a and IL-6 in blood. These ndings suggest that PPAR-c agonists may not be useful for the treatment of acute in ammation (78) .
CONCLUSIONS
Several studies have convincingly shown that PPARs play important roles expanding beyond the glucose and lipid metabolism (diabetes and obesity) with functions on vascular biology and in ammation, including atherosclerosis. PPARs (PPAR-a and PPAR-c ) exert their bene cial effects through regulation of cytokine production, adhesion molecule expression on the endothelial cells, brinolysis, and modulation of monocyte-derived macrophages, including apoptosis. Along with the discovery of PPARs in vascular and in ammatory cells, the implication of PPARs as important modulators of in ammatory process through direct effects on these cells is still growing. PPARs presence in the vascular cells also opens up the possibility of developing new therapeutic agents that speci cally modulate these nuclear receptors to control various in ammatory diseases, including atherosclerosis, rheumatoid arthritis, and Alzheimer's disease. However, further studies are needed to assess the long-term consequences of PPAR activation in vivo with particular consideration to some of the undesirable in vitro study ndings such as upregulation of activated macrophages, increased foam cell differentiation, and enhanced activity macrophages to internalize oxidized LDL.
